Kronik lenfosittik lösemi tedavisinde kullanılan idelalisib’ in etki mekanizması aşağıdakilerden hangisinde doğru olarak verilmiştir?
A) Anti-apoptotik protein olan Bcl-2’nin inhibisyonu
B) Poly-ADP riboz polimeraz inhibisyonu
C) Epitelyal hücre adezyon molekülü (EPCAM) inhibisyonu
D) Platelet kaynaklı büyüme faktör reseptör (PDGFR) inhibisyonu
E) PI3K (fosfotidil inozitol-4,5-bifosfat 3 kinaz) İnhibisyonu ******
Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)
1-Idelalisib; PIK3CD inhibitor relapsed or refractory chronic lymphocytic leukemia (CLL), relapsed small lymphocytic lymphoma, follicular lymphoma (FL)
2-Copanlisib; PIK3CA / PIK3CD inhibitör, relapsed follicular lymphoma
3-Duvelisib; PIK3CD / PIK3CG inhibitör, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), relapsed or refractory follicular lymphoma
4-Alpelisib; PIK3CA inhibitör, HR-positive and HER2/neu-negative breast cancer
5-Umbralisib; PIK3CD and casein kinase CSNK1E inhibitör, relapsed or refractory marginal zone lymphoma (MZL), relapsed or refractory follicular lymphoma after at least three prior lines of systemic therapy.
6-Leniolisib; PIK3CD inhibitor, activated PI3K delta syndrome (APDS) / PASLI disease